Lonza has launched fully customisable, cryopreserved Leukopaks. The frozen Leukopaks will enable long-distance shipping of leukapheresis products without the concern of reduced cell viability encountered with fresh Leukopaks. Being suitable for long-term storage in research labs, the cryopreserved Leukopaks will also allow immediate access to viable cells for greater convenience and workflow flexibility.
Andrew Winner, Product Manager, Lonza Bioscience, said: “The short viability window of fresh Leukopaks means researchers are at the mercy of donor and shipping schedules – and any logistical delays can wreak havoc on project costs and the quality of research results. By offering cryopreserved Leukopaks, we are expanding our ability to deliver high-viability cell products internationally, and the rapid availability of stored cryopreserved Leukopaks means our customers are better able to adhere to uncompromising research timelines.”
Lonza’s cryopreserved Leukopaks are available in a range of sizes, including packs of 2.5, 5 and 9.5 billion cells, which can be subdivided into separate smaller bags for greater convenience. Specific donor characteristics like age, gender and Human Leukocyte Antigen (HLA) type are also available, with a range of recallable donors and several product testing options.
